New shot aims to tame rare kidney disease in Mid-Stage trial
NCT ID NCT06830395
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times
Summary
This study tests a new drug, CM313, in 106 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug is safe and helps control the disease. Participants will receive the drug as a shot, and researchers will monitor side effects and how well the kidneys respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.